معرفی
Berit Gravdehaug is a Lecturer in the Division of Surgery at the University of Oslo. Her research focuses on breast cancer treatment optimization, cardio-oncology, and patient-centered approaches to genetic testing. She has contributed to studies assessing biomarkers like Prosigna for treatment decisions and the prevention of cardiac dysfunction during cancer therapy. Her work includes the PRADA trial, investigating cardioprotective strategies, and the EMIT-1 study on genetic testing practices.
Key research interests include hormonal therapy cross-resistance, neoadjuvant treatment outcomes, and imaging-guided diagnostic techniques. Dr. Gravdehaug’s publications span clinical trials, biomarker analysis, and patient experience studies, emphasizing translational research in oncology and cardiology.
